In IBD, PPARα activation represses NF-κB signaling, which decreases the inflammatory cytokine production by different cell types, whereas PPARγ ligands can inhibit activation of macrophages and the production of inflammatory cytokines, such as TNF-α, interleukin (IL)-6, and Il-1β [24]. Here, PPARG is linked to inflammatory bowel disease.